Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation

B. Simonsson, T. Tötterman, P. Hokland, F. Lauria, A. M. Carella, M. N. Fernandez, C. Rozman, A. Ferrant, T. De Witte, A. R. Zander, K. Meier, F. Hansson, B. I. Nilsson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6.9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.

Original languageEnglish
Pages (from-to)1121-1127
Number of pages7
JournalBone Marrow Transplantation
Volume25
Issue number11
Publication statusPublished - 2000

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Placebos
Recurrence
Natural Killer Cells
roquinimex
Survival
Platelet Count
Leukemia
Cell Count
Bone Marrow
Body Weight

Keywords

  • ABMT
  • AML
  • Linomide
  • Roquinimex

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Simonsson, B., Tötterman, T., Hokland, P., Lauria, F., Carella, A. M., Fernandez, M. N., ... Nilsson, B. I. (2000). Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplantation, 25(11), 1121-1127.

Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. / Simonsson, B.; Tötterman, T.; Hokland, P.; Lauria, F.; Carella, A. M.; Fernandez, M. N.; Rozman, C.; Ferrant, A.; De Witte, T.; Zander, A. R.; Meier, K.; Hansson, F.; Nilsson, B. I.

In: Bone Marrow Transplantation, Vol. 25, No. 11, 2000, p. 1121-1127.

Research output: Contribution to journalArticle

Simonsson, B, Tötterman, T, Hokland, P, Lauria, F, Carella, AM, Fernandez, MN, Rozman, C, Ferrant, A, De Witte, T, Zander, AR, Meier, K, Hansson, F & Nilsson, BI 2000, 'Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation', Bone Marrow Transplantation, vol. 25, no. 11, pp. 1121-1127.
Simonsson B, Tötterman T, Hokland P, Lauria F, Carella AM, Fernandez MN et al. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplantation. 2000;25(11):1121-1127.
Simonsson, B. ; Tötterman, T. ; Hokland, P. ; Lauria, F. ; Carella, A. M. ; Fernandez, M. N. ; Rozman, C. ; Ferrant, A. ; De Witte, T. ; Zander, A. R. ; Meier, K. ; Hansson, F. ; Nilsson, B. I. / Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. In: Bone Marrow Transplantation. 2000 ; Vol. 25, No. 11. pp. 1121-1127.
@article{9669d91726a3457aac71aa91b641ad43,
title = "Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation",
abstract = "Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6.9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.",
keywords = "ABMT, AML, Linomide, Roquinimex",
author = "B. Simonsson and T. T{\"o}tterman and P. Hokland and F. Lauria and Carella, {A. M.} and Fernandez, {M. N.} and C. Rozman and A. Ferrant and {De Witte}, T. and Zander, {A. R.} and K. Meier and F. Hansson and Nilsson, {B. I.}",
year = "2000",
language = "English",
volume = "25",
pages = "1121--1127",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation

AU - Simonsson, B.

AU - Tötterman, T.

AU - Hokland, P.

AU - Lauria, F.

AU - Carella, A. M.

AU - Fernandez, M. N.

AU - Rozman, C.

AU - Ferrant, A.

AU - De Witte, T.

AU - Zander, A. R.

AU - Meier, K.

AU - Hansson, F.

AU - Nilsson, B. I.

PY - 2000

Y1 - 2000

N2 - Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6.9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.

AB - Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6.9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.

KW - ABMT

KW - AML

KW - Linomide

KW - Roquinimex

UR - http://www.scopus.com/inward/record.url?scp=0342264631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342264631&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 1121

EP - 1127

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -